People

Christian Angermayer is an entrepreneur and investor as well as the founder of Apeiron Investment Group, his family office and asset management business. Apeiron focuses on Life Sciences, FinTech/InsurTech/PropTech & Crypto and DeepTech (e.g. SpaceTech, AI, etc.). In these sectors, Apeiron has a deep experience and a proven track record of more than 20 years.

Shannon Thyme Klinger is the Chief Legal Officer of Moderna, Inc. She has over 25 years of global leadership experience in the pharmaceutical industry across a wide range of functional areas, including legal, compliance, IP, licensing, mergers and acquisitions, public/government affairs, communications, risk management, quality, and regulatory affairs. She is a recognized thought leader in the areas of ESG, social intrapreneurship, and diversity, equity, and inclusion.

Throughout her career, she has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, and championing the responsible use of data.

Ms. Klinger currently serves as a member of the board of directors of the Association of Corporate Counsel and has previously served on the board of directors of the SIX Group and Rafael Holdings Inc.

As an independent public board member & chair (NASDAQ & CSX) Teresa DeLuca’s experience includes a SPAC transition, an IPO and replacing private equity firms. Further, as a founding chair for three separate committees (compensation, compliance and governance committees), she has created both structure and process while leading strategic and operational discussions.

Teresa DeLuca’s most recent public board seat, at 180 Life Sciences (NASDAQ: ATNF), where she serves as chair of Compensation Committee and member of Nominating Governance Committee, was from a SPAC transaction.

Teresa DeLuca is an advocate for strong board governance and she has demonstrated that commitment through continued professional education and maintaining good standing with the National Association of Corporate Directors (NACD) as a Board Leadership Fellow, Master Level.

Teresa DeLuca has passed the NACD’s “Directorship Certified” (NACD.DC) examination, earned the Carnegie Mellon Cybersecurity certificate and was named “2020 Director to Watch” in the Directors & Board Annual Report.

Greg Weaver has over 25 years of corporate strategic financial leadership as a career Chief Financial Officer (CFO) and board member in the biotech/medtech industry, guiding fundraising, capital markets, investor relations, financial reporting, and business operations planning. Greg Weaver currently serves as the CFO of BioIntelliSense, a US privately-held medtech company. Greg Weaver has served as a public biotech board member continuously since 2005, including as audit and compensation committee chairman, currently with Atossa Therapeutics, and formerly with Noxxon/TME Pharma N.V. (Berlin), Egalet Pharma, Celsion Therapeutics, and Oryzon (Barcelona).

Greg Weaver holds a B.S. in Accounting from Trinity University (Texas), an MBA from Boston College, and a US CPA certification. Greg Weaver has served in the US Air Force. He also serves on the board of the not-for-profit HarborPath, focused on serving patients suffering from AIDS and opioid addiction.

Aksana brings 10+ years of experience in the life science and healthcare industry, including early-stage business development, company building, and venture. At Rejuveron she oversees investments, deal sourcing and contributes to strategic expansion of our portfolio companies.

Caleb has over 20 years of international finance experience across multiple sectors and geographies. He has worked in CFO roles as well as investment banking and over the course of his career has executed ~$30 billion of equity and debt financings spanning numerous industries and markets (US, Europe, and Asia).

Gabor is a seasoned biotech executive whose expertise spans drug discovery and venture capital financing. He has spent close to a decade developing immunotherapy programs and has executed a wide range of investments in both the private and public biotech sectors. In his current role, he focuses on strategic planning, fundraising efforts, and building strategic partnerships with leading pharmaceutical companies.

Aaron is a seasoned investor and operator of life science companies. He has provided expert counsel on numerous types of capital market issuances, emerging markets debt, covered bonds, high yield and restructurings. He has lead investor relations experience across several portfolios.

Estela is a Venture Developer at Rejuveron Life Sciences AG, specializing in the biotech and longevity sectors. She plays a key role in identifying and evaluating new opportunities, conducting thorough due diligence, and providing scientific assessments to inform strategic planning. With a strong foundation in neuroscience and business development, she actively contributes to financial strategies, event coordination, and leading comprehensive market analyses, while maintaining a strong network within the industry.

With over a decade of executive assistance experience, Lisa has transitioned into the role of Operations Manager, bringing her expertise in optimizing efficiency and streamlining processes. Fluent in English, German, and French, she excels in fostering collaboration across teams. Lisa’s focus now includes overseeing operations, ensuring smooth workflows, and driving organizational success in dynamic startup environments.

Aksana brings 10+ years of experience in the life science and healthcare industry, including early-stage business development, company building, and venture. At Rejuveron she oversees investments, deal sourcing and contributes to strategic expansion of our portfolio companies.

Caleb has over 20 years of international finance experience across multiple sectors and geographies. He has worked in CFO roles as well as investment banking and over the course of his career has executed ~$30 billion of equity and debt financings spanning numerous industries and markets (US, Europe, and Asia).

Gabor is a seasoned biotech executive whose expertise spans drug discovery and venture capital financing. He has spent close to a decade developing immunotherapy programs and has executed a wide range of investments in both the private and public biotech sectors. In his current role, he focuses on strategic planning, fundraising efforts, and building strategic partnerships with leading pharmaceutical companies.

Christian Angermayer is an entrepreneur and investor as well as the founder of Apeiron Investment Group, his family office and asset management business. Apeiron focuses on Life Sciences, FinTech/InsurTech/PropTech & Crypto and DeepTech (e.g. SpaceTech, AI, etc.). In these sectors, Apeiron has a deep experience and a proven track record of more than 20 years.

Aksana brings 10+ years of experience in the life science and healthcare industry, including early-stage business development, company building, and venture. At Rejuveron she oversees investments, deal sourcing and contributes to strategic expansion of our portfolio companies.

Shannon Thyme Klinger is the Chief Legal Officer of Moderna, Inc. She has over 25 years of global leadership experience in the pharmaceutical industry across a wide range of functional areas, including legal, compliance, IP, licensing, mergers and acquisitions, public/government affairs, communications, risk management, quality, and regulatory affairs. She is a recognized thought leader in the areas of ESG, social intrapreneurship, and diversity, equity, and inclusion.

Throughout her career, she has focused on driving long-term business performance and building trust with society, including ensuring access to medicine, protecting innovation with intellectual property, and championing the responsible use of data.

Ms. Klinger currently serves as a member of the board of directors of the Association of Corporate Counsel and has previously served on the board of directors of the SIX Group and Rafael Holdings Inc.

As an independent public board member & chair (NASDAQ & CSX) Teresa DeLuca’s experience includes a SPAC transition, an IPO and replacing private equity firms. Further, as a founding chair for three separate committees (compensation, compliance and governance committees), she has created both structure and process while leading strategic and operational discussions.

Teresa DeLuca’s most recent public board seat, at 180 Life Sciences (NASDAQ: ATNF), where she serves as chair of Compensation Committee and member of Nominating Governance Committee, was from a SPAC transaction.

Teresa DeLuca is an advocate for strong board governance and she has demonstrated that commitment through continued professional education and maintaining good standing with the National Association of Corporate Directors (NACD) as a Board Leadership Fellow, Master Level.

Teresa DeLuca has passed the NACD’s “Directorship Certified” (NACD.DC) examination, earned the Carnegie Mellon Cybersecurity certificate and was named “2020 Director to Watch” in the Directors & Board Annual Report.

Greg Weaver has over 25 years of corporate strategic financial leadership as a career Chief Financial Officer (CFO) and board member in the biotech/medtech industry, guiding fundraising, capital markets, investor relations, financial reporting, and business operations planning. Greg Weaver currently serves as the CFO of BioIntelliSense, a US privately-held medtech company. Greg Weaver has served as a public biotech board member continuously since 2005, including as audit and compensation committee chairman, currently with Atossa Therapeutics, and formerly with Noxxon/TME Pharma N.V. (Berlin), Egalet Pharma, Celsion Therapeutics, and Oryzon (Barcelona).

Greg Weaver holds a B.S. in Accounting from Trinity University (Texas), an MBA from Boston College, and a US CPA certification. Greg Weaver has served in the US Air Force. He also serves on the board of the not-for-profit HarborPath, focused on serving patients suffering from AIDS and opioid addiction.